

Capital Markets Day

## Siemens Healthineers Announces New Strategy Phase “Elevating Health Globally”, Mid-term Targets

- **Market and innovation leadership with healthcare AI as accelerator**
- **Accelerating clinical impact through focusing on non-communicable diseases and driving customer impact to the next level**
- **New “Precision Therapy” segment combines Varian, Advanced Therapies and Ultrasound**
- **FY 2027-2030 annual revenue growth of 6-9% from synergetic core of Imaging and Precision Therapy**
- **Double-digit group EPS growth and robust free cash flows**
- **Diagnostics to pursue its own strategy in its own set-up**

Siemens Healthineers announced mid-term financial targets for its new strategy phase, which will focus the company’s unique strengths including healthcare artificial intelligence and custom-built partnerships on tackling four of the most prevalent diseases<sup>1</sup>. Financial reporting is to be structured along three segments, following the strategic logic of “Elevating Health Globally”. Imaging will focus on disease prevention and detection; a new segment, Precision Therapy, will combine Varian, Advanced Therapies and Ultrasound to focus on treatment; and Diagnostics will pursue its own strategy, enabled by its own set-up.<sup>2</sup>

For fiscal years 2027-2030, Siemens Healthineers is targeting annual revenue growth of 6-9% from Imaging and Precision Therapy combined, while Diagnostics is expected to improve towards mid-single-digit growth. For the group, this translates to a 5-7% growth rate. In adjusted earnings per share, the company targets double-digit percentage growth annually, it said at its Capital Markets Day in London.

The ultimate objective of the new strategy is greater impact on patient care, using artificial intelligence as an important lever to help healthcare providers work in a more efficient and personalized way. As non-communicable diseases increasingly burden emerging as well as more developed economies, Siemens Healthineers is focusing on stroke, cancer, cardiovascular diseases and neurodegenerative diseases. With the long-awaited emergence of treatments for Alzheimer’s disease, for example, the tools the company offers to help select and monitor patients are gaining relevance in this important new field.

“In the Elevating phase of our strategy, we want to make an impact on the health of the world’s 8 billion people by fighting the diseases they fear, helping more people live with hope,” said Chief Executive Bernd Montag. “We want to take our company to the next level, using our global presence and experience to help our customers increase efficiency, drive clinical excellence and expand healthcare access.”

Siemens Healthineers will further expand its Value Partnerships, which already connect the company with more than 200 major customers around the world and are an important source of recurring revenues. Inspired by these, new Value Programs are being customized for healthcare providers to support them in tackling specific non-communicable diseases. And, in emerging markets, the company aims to further increase its impact and sustain its double-digit growth path.

“We have defined clear financial targets for the medium term until 2030,” said Chief Financial Officer Jochen Schmitz. “A comprehensive financial framework will form the basis for reliable revenue and profit growth and free cash flow generation for sound capital allocation to drive sustainable shareholder value.”

For the period 2027-2030, the company expects annual revenue growth for the Imaging segment to be in the mid- to high-single-digit-percentage range, with margin expansion thanks to economies of scale. Precision Therapy is expected to achieve high-single-digit-percentage revenue growth each year, while increasing its margin annually by about 100 basis points on average. The Diagnostics segment is expected to approach mid-single-digit-percentage growth, and to increase its margin into the mid-teens.

On cash conversion, Siemens Healthineers targets a sustainable rate of 0.8 to 0.9 for the period till 2030, building on the very healthy cash-generation levels of recent years through higher earnings and improved operating working capital. This will help the company to further deleverage from 4.2x net debt/EBITDA following the Varian closing in 2021 to 2.5x within the next two years. Providing that a successful deleveraging and a higher free float take place, share buybacks could become possible. The company maintains its commitment to a stable to progressive dividend.

<sup>1</sup> 75% of global deaths are attributed to non-communicable diseases ([www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases](http://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases))

<sup>2</sup> The new reporting segments comprise the following technologies: Imaging includes computed tomography, magnetic resonance imaging, molecular imaging, X-ray and digital & automation; Precision Therapy includes radiation oncology, interventional oncology, mobile and fixed c-arms, ultrasound and digital oncology; Diagnostics includes core lab solutions, specialty lab solutions and point of care

Further information on Siemens Healthineers Capital Markets Day 2025 can be found [here](#).

## Media contact

Georgina Prodhan

+44 7808 828799; [Georgina.Prodhan@siemens-healthineers.com](mailto:Georgina.Prodhan@siemens-healthineers.com)

Ulrich Kuenzel

+49 162 2433492; [Ulrich.Kuenzel@siemens-healthineers.com](mailto:Ulrich.Kuenzel@siemens-healthineers.com)

Visit the [Siemens Healthineers Press Center](#).

Subscribe to our [“Medtech matters” newsletter on LinkedIn](#).

**Siemens Healthineers** pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at [siemens-healthineers.com](https://www.siemens-healthineers.com).